Guoyin Liu | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Guoyin Liu | Molecular Biology | Best Researcher Award 

Attending physician and associate professor, at Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210093, China.

Dr. Guoyin Liu is an accomplished attending physician and associate professor at Jinling Hospital, Nanjing University, renowned for his expertise in orthopedics, inflammatory signaling, and regenerative medicine. Holding a PhD from Nanjing Medical University, he specializes in endoplasmic reticulum (ER) molecular chaperones such as GRP78/Bip and their role in critical orthopedic conditions including rheumatoid arthritis, osteoarthritis, chronic wounds, and periprosthetic osteolysis. Beyond molecular research, he pioneers innovative treatments like extracorporeal shock wave therapy, needle-knife therapy, and restorative laminoplasty techniques for spinal reconstruction. His translational research bridges basic science with clinical applications, contributing to novel interventions for musculoskeletal disorders. With an impressive portfolio of high-impact publications, key research grants, patents, and editorial board memberships, Dr. Liu exemplifies a commitment to advancing orthopedic science and patient care. His innovative contributions continue to shape the future of orthopedic diagnostics and treatments, fostering breakthroughs in bone regeneration and inflammatory disease management.

Professional Profile

Scopus

ORCID

🎓 Education 

Dr. Liu completed his PhD at Nanjing Medical University, focusing on the molecular mechanisms underlying inflammatory bone loss and tissue degeneration. His academic foundation integrates basic medical sciences, clinical orthopedics, and bioengineering approaches, enabling him to investigate complex orthopedic diseases at the cellular and molecular levels. During his training, he mastered advanced experimental techniques, including finite element biomechanical analysis, tissue engineering methodologies, and translational clinical trials. Dr. Liu expanded his academic horizon through specialized workshops in regenerative medicine, musculoskeletal biomechanics, and immunomodulation therapies. His education laid the groundwork for his pioneering research on GRP78/Bip signaling pathways in chronic musculoskeletal diseases. By blending clinical insights with experimental rigor, he has become a leading voice in developing innovative therapies for orthopedic patients. His educational journey reflects a seamless integration of theory and practice, empowering him to address both clinical challenges and fundamental biomedical questions with cutting-edge research approaches.

💼 Experience 

With over 15 years of combined clinical and research experience, Dr. Guoyin Liu has established himself as a leading expert in orthopedic surgery, translational research, and regenerative medicine. As an Attending Physician and Associate Professor at Jinling Hospital, he manages complex cases such as spinal deformities, chronic joint diseases, and osteolytic conditions. His academic tenure includes supervising multidisciplinary research projects funded by National Natural Science Foundation of China and provincial grants focusing on inflammatory pathways and bone regeneration. He has innovated surgical techniques like restorative laminoplasty with miniplate fixation, which has improved postoperative spinal stability and patient recovery outcomes. His extensive clinical experience is complemented by editorial board appointments in reputed international journals, reflecting his scientific leadership. Dr. Liu’s dual role as a clinician and researcher enables him to directly translate benchside discoveries into bedside applications, ensuring tangible benefits for patients suffering from chronic orthopedic disorders.

🔬 Research Interests 

Dr. Liu’s research is centered on cellular stress responses and inflammatory pathways in orthopedic diseases, with a special focus on endoplasmic reticulum molecular chaperones (GRP78/Bip) and their dual intracellular and extracellular roles. He investigates how particle-induced osteolysis, rheumatoid arthritis, and intervertebral disc degeneration are driven by inflammatory cascades, aiming to develop targeted molecular therapies. Another significant area of his research explores chemical chaperones like 4-Phenylbutyrate, which mitigate ER stress and improve bone regeneration. Dr. Liu also advances biomechanical engineering solutions, analyzing finite element models to improve spinal fixation techniques. Additionally, he integrates shockwave therapy, corticosteroid injections, and minimally invasive interventions for managing chronic orthopedic pain. His translational approach bridges basic science, bioengineering, and clinical orthopedics, leading to innovative strategies that reduce surgical complications and improve musculoskeletal repair. Through his research, Dr. Liu aims to redefine the diagnosis, prevention, and treatment of bone and joint diseases in aging populations.

🏆 Awards & Honors 

Dr. Liu has received numerous academic and clinical recognitions for his groundbreaking work in orthopedics. He was honored with the Third Prize for Military Science & Technology Progress for elucidating the TIM3 signaling pathway in osteoarthritis during military training-related injuries. Additionally, he received the Third Award for Nanjing Science & Technology Progress for identifying the role of recombinant BMP-1 in periprosthetic osteolysis. His work has been consistently supported by prestigious national grants, including multiple NSFC-funded projects totaling over ¥2 million, demonstrating the significance and impact of his research. Beyond awards, his appointment to editorial boards of leading orthopedic and bioengineering journals highlights his global recognition in the field. Dr. Liu’s innovative surgical methods, such as restorative laminoplasty with H-shaped miniplates, have been acknowledged as transformative in spinal reconstruction. These accolades collectively recognize his outstanding contribution to orthopedic research, surgical innovation, and patient care.

📚 Top Noted Publications 

Dr. Liu’s publications span orthopedic biomechanics, inflammatory pathways, and regenerative medicine, widely cited in the global research community. Key works include:

🛠️ Biomechanical Stability of Miniplates in Restorative Laminoplasty

Title: Comparative Biomechanical Stability of the Fixation of Different Miniplates in Restorative Laminoplasty after Laminectomy: A Finite Element Study
Authors: Guoyin Liu, Weiqian Huang, Nannan Leng, Peng He, Xin Li, Muliang Lin, Zhonghua Lian, Yong Wang, Jianmin Chen, Weihua Cai
Journal: Bioengineering (Basel)
Year / Volume / Issue: 2024; 11(5):519
DOI: 10.3390/bioengineering11050519 PubMed+15MDPI+15ResearchGate+15
Highlights: Used a finite element model (L2–L4) to compare H‑shaped, L‑shaped, and two‑hole miniplates. The H‑shaped design showed superior stability, especially in axial rotation and flexion/extension PubMedMDPI.

Biomechanical Reconstruction of the Posterior Complex in Laminoplasty

Title: Biomechanical evaluation of reconstruction of the posterior complex in restorative laminoplasty with miniplates
Authors: Jianmin Chen, Guoyin Liu, Tianyi Bao, Yuansheng Xu, Hu Luo, Yu Wu, Dawei Cai, Feng Qin, Jianning Zhao
Journal: BMC Musculoskeletal Disorders
Year / Volume / Article: 2023; 24(1):298
DOI: 10.1186/s12891-023-06380-3 PubMedOUCI
Highlights: Cadaveric 3D-printed L4 models under static/dynamic loading. H‑shaped miniplates outperformed L‑shaped and two-hole systems, preventing lamina collapse or plate breakage PubMedResearchGate.

Macrophage Apoptosis Pathways in Periprosthetic Osteolysis

Title: Apoptotic pathways of macrophages within osteolytic interface membrane in periprosthetic osteolysis
Journal: APMIS
Year: 2017
Details: Demonstrates that wear particles at implant interfaces accelerate macrophage apoptosis via ER-stress and mitochondrial dysfunction, which exacerbates osteolysis PubMedPhysiology Journals.

Endoplasmic Reticulum Stress and Osteolysis

Title: Endoplasmic reticulum stress-mediated inflammatory signaling pathways within the osteolytic periosteum and interface membrane in particle-induced osteolysis
Authors: Guoyin Liu, Naicheng Liu, Yuansheng Xu, Yunfan Ti, Jiangning Chen, Jianmin Chen, Junfeng Zhang, Jianning Zhao
Journal: Cell and Tissue Research
Year / Issue / Pages: 2016 Feb; 363(2):427–447
DOI: 10.1007/s00441-015-2205-9 PubMedSpringerLink
Highlights: Particle debris induces ER stress in macrophages, triggering IRE1α, GRP78/BiP, NF‑κB pathways, elevating pro-inflammatory cytokines (TNF‑α, IL‑1β, IL‑6). 4‑PBA effectively reduced ER-stress and osteolysis in murine models .

Conclusion

Dr. Guoyin Liu’s outstanding contributions to orthopedic research, innovative therapies, and patented medical devices make him a highly suitable candidate for the Best Researcher Award. His work bridges basic molecular research with clinical applications, significantly improving diagnosis, treatment, and rehabilitation of complex musculoskeletal disorders.

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.